NRS
AZN icon

Neville Rodie & Shaw’s AstraZeneca AZN Stock Holding History

Neville Rodie & Shaw’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$250K Hold
1,318
– – 0.02% 218
2026
Q1 		$260K Buy
+1,318
New +$254K 0.02% 216

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Neville Rodie & Shaw's AZN Position: Q2 2026 in Review

Neville Rodie & Shaw held its AstraZeneca (AZN) position steady in Q2 2026 at 1,318 shares worth $250K. The position accounts for 0.02% of the portfolio, ranked #218.

Neville Rodie & Shaw first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $260K in Q1 2026. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Neville Rodie & Shaw held 1,318 shares of AstraZeneca worth $250K as of Q2 2026.
  • Neville Rodie & Shaw left its AstraZeneca share count unchanged in Q2 2026.
  • AstraZeneca made up 0.02% of Neville Rodie & Shaw's portfolio in Q2 2026, its #218 holding.
  • Neville Rodie & Shaw first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
  • Neville Rodie & Shaw's AstraZeneca position peaked at $260K in Q1 2026.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Neville Rodie & Shaw's 13F filing for Q2 2026, filed 6 Jul 2026.